Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort.

TitreFrequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort.
Publication TypeJournal Article
Year of Publication2018
AuthorsGodat, S, Fournier, N, Safroneeva, E, Juillerat, P, Nydegger, A, Straumann, A, Vavricka, S, Biedermann, L, Greuter, T, Fraga, M, Abdelrahman, K, Hahnloser, D, Sauter, B, Rogler, G, Michetti, P, Schoepfer, AM
Corporate AuthorsGroup, SIBDCohort
JournalEuropean journal of gastroenterology & hepatology
Volume30
Issue6
Pagination612-620
Date Published06/2018
DOI10.1097/MEG.0000000000001078
ISSN1473-5687
Mots-clés80 and over, Adolescent, Adult, Adverse Drug Reaction Reporting Systems, Aged, Anti-Inflammatory Agents/adverse effects, Chi-Square Distribution, Child, Colitis, combination, Crohn Disease/diagnosis, Crohn Disease/drug therapy, Crohn Disease/epidemiology, Drug Therapy, Drug-Related Side Effects and Adverse Reactions/diagnosis, Drug-Related Side Effects and Adverse Reactions/epidemiology, Female, Gastrointestinal Agents/adverse effects, Humans, Infant, Logistic Models, Male, Middle Aged, Multivariate Analysis, Odds Ratio, Preschool, Retrospective Studies, Risk Factors, Switzerland/epidemiology, Ulcerative/diagnosis, Ulcerative/drug therapy, Ulcerative/epidemiology, Young Adult
Abstract

BACKGROUND AND AIM: Systematic analyses of inflammatory bowel disease (IBD) drug-related side effects necessitating treatment cessation in large cohorts of patients with IBD are scarce. We aimed to assess the frequency and type of drug-related side effects requiring drug cessation in patients included in the Swiss IBD Cohort.

PATIENTS AND METHODS: A retrospective review was performed of data from the Swiss IBD Cohort physician questionnaires documenting a treatment cessation for the following drug categories: aminosalicylates, topical and systemic steroids, thiopurines, methotrexate, tumor necrosis factor-antagonists, and calcineurin inhibitors (tacrolimus, cyclosporine).

RESULTS: A total of 3192 patients were analyzed, of whom 1792 (56.1%) had Crohn's disease, 1322 (41.4%) had ulcerative colitis, and 78 (2.5%) had IBD unclassified. Of 3138 patients treated with IBD drugs, 2129 (67.8%) presented with one or several drug-related side effects necessitating drug cessation. We found a significant positive correlation between the number of concomitantly administered IBD drugs and the occurrence of side effects requiring drug cessation (P<0.001). Logistic regression modeling identified Crohn's disease diagnosis [odds ratio (OR)=1.361, P=0.017], presence of extraintestinal manifestations (OR=2.262, P<0.001), IBD-related surgery (OR=1.419, P=0.006), and the increasing number of concomitantly used IBD drugs [OR=2.007 (P<0.001) for two concomitantly used IBD drugs; OR=3.225 (P<0.001) for at least three concomitantly used IBD drugs] to be associated significantly with the occurrence of IBD drug-related adverse events that necessitated treatment cessation.

CONCLUSION: Physicians should keep in mind that the number of concomitantly administered IBD drugs is the main risk factor for drug-related adverse events necessitating treatment cessation.

Alternate URL

http://www.ncbi.nlm.nih.gov/pubmed/29384798?dopt=Abstract

First publication date (online)

01/2018

WOS ID (UT)

000431298900004

Alternate JournalEur J Gastroenterol Hepatol
Citation Key / SERVAL ID8571
Peer reviewRefereed
PubMed ID29384798

                         

IUMSP | www.iumsp.ch
Institut universitaire de médecine sociale et préventive
Route de la Corniche 10, 1010 Lausanne - Switzerland
+41 21 314 72 72 | dess.info@unisante.ch

Go to top